http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Newly Released Clinical Data Demonstrates Substantial Improvement in Overall Health-Related Quality of Life in Patients with Painful Diabetic Neuropathy Treated with Nevro HFX Spinal Cord Stimulation
-
Clinical Data Presented at American Diabetes Association 82nd Scientific Sessions Reinforce Significant and Durable Benefits of Nevro's HFX 10 kHz Therapy
-
Nevro Announces SENZA-PDN Clinical Data Presentations at the American Diabetes Association 82nd Scientific Sessions
-
Nevro Reports First Quarter 2022 Financial Results, Provides Second Quarter 2022 Guidance and Reiterates Full-Year 2022 Guidance
-
Nevro to Report First Quarter 2022 Financial Results
-
Nevro Announces Positive Medicare Coverage Update from Noridian for the Treatment of Painful Diabetic Neuropathy
-
Nevro Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides First Quarter and Full-Year 2022 Guidance
-
Nevro to Participate in Wells Fargo 2022 MedTech R&D Spotlight Call Series
-
Nevro (NVRO) Reports Publication of 12-Month Data from SENZA-NSRBP Trial
-
Nevro Announces Publication of 12-Month Data from SENZA-NSRBP Randomized Controlled Trial in Journal of Neurosurgery: Spine
-
Nevro to Present at Citi's 2022 Virtual Healthcare Conference
-
Nevro Named to 2022 Bloomberg Gender-Equality Index
-
Nevro (NVRO) Responds to Approval of Metronic's painful diabetic neuropathy
-
Nevro Responds to Competitor's Announcement of FDA Approval for Painful Diabetic Neuropathy
-
Nevro to Report Fourth Quarter and Full-Year 2021 Financial Results
-
Nevro (NVRO) Granted FDA Approval for Expanded Labeling for its 10 kHz High Frequency Spinal Cord Stimulation System
-
Nevro Announces FDA Approval for Expanded Labeling for its 10 kHz High Frequency Spinal Cord Stimulation System for Treatment of Non-Surgical Refractory Back Pain (NSRBP)
-
Nevro (NVRO) Presents Data Reinforcing Significant and Durable Benefits of Nevro's 10 kHz Therapy
-
Clinical Data Presented at 2022 North American Neuromodulation Society (NANS) Annual Meeting Reinforce Significant and Durable Benefits of Nevro's 10 kHz Therapy
-
Nevro (NVRO) Reports Prelim Q4 Results
-
Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2021 Revenue
-
Nevro (NVRO) Granted UnitedHealthcare Coverage for High-Frequency 10 kHz Therapy for the Treatment of Painful Diabetic Neuropathy
-
Nevro Announces UnitedHealthcare Coverage for High-Frequency 10 kHz Therapy for the Treatment of Painful Diabetic Neuropathy
-
Nevro (NVRO) Announces Settlement of IP Litigation with Nalu Medical
-
Nevro Announces Settlement of IP Litigation with Nalu Medical
-
CORRECTING AND REPLACING -- Nevro to Present at 40th Annual J.P. Morgan Healthcare Conference
-
Nevro Announces Three Podium Presentations from SENZA-PDN and SENZA-NSRBP Clinical Trials Have Been Accepted for Late-Breaking Abstract Sessions at NANS 2022 Annual Meeting
-
Nevro to Present at 40th Annual J.P. Morgan Healthcare Conference
-
Nevro Announces Two Health Economic Poster Presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2021 Meeting
-
Nevro Announces Three Important Clinical Data Publications for Treating Painful Diabetic Neuropathy with 10 kHz Therapy
-
Nevro Reports Third Quarter 2021 Financial Results and Provides Fourth Quarter Guidance
-
Nevro (NVRO) Infringed Two Boston Scientific Patents, Owes $20M
-
Nevro Announces Update in Patent Litigation with Boston Scientific
-
Nevro to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
-
Nevro to Report Third Quarter 2021 Financial Results
-
Nevro (NVRO) Appoints Sri Kosaraju to its Board
-
Nevro Announces Director Appointment
-
Nevro to Present at Baird 2021 Global Healthcare Conference
-
Nevro to Present at Morgan Stanley 19th Annual Global Healthcare Conference
-
Nevro to Present at Wells Fargo Virtual Healthcare Conference
-
Nevro Reports Second Quarter 2021 Financial Results and Provides Third Quarter of 2021 Guidance
-
Nevro (NVRO) Announces FDA Approval for Senza System for Chronic Pain Associated with PDN
-
Nevro Announces FDA Approval of its 10 kHz High Frequency Spinal Cord Stimulation Therapy for Treatment of Chronic Pain Associated with Painful Diabetic Neuropathy (PDN)
-
Nevro to Report Second Quarter 2021 Financial Results
-
Nevro (NVRO) Announces SENZA-PDN Clinical Data Presentation at the American Diabetes Association 81st Scientific Sessions
-
Nevro Announces SENZA-NSRBP Clinical Data Presentation at the American Society of Interventional Pain Physicians 23rd Annual Meeting
-
Nevro Announces SENZA-PDN Clinical Data Presentation at the American Diabetes Association 81st Scientific Sessions
-
Nevro to Host Virtual Analyst & Investor Briefing
-
Nevro Reports First Quarter 2021 Financial Results and Updates 2021 Guidance
-
Nevro to Present at UBS Global Healthcare Virtual Conference

